Welcome to the Hill Lab
The mission of the Hill Lab is to develop a deep mechanistic understanding of ovarian cancer development and progression which we will harness to make ovarian cancer a more manageable disease for all patients through the development of effective methods of early detection, more personalized treatment, and better therapeutic strategies.
In pursuit of this mission, the Hill lab focuses on understanding the role of the DNA damage response in ovarian carcinogenesis, tumor evolution, the anti-tumor immune response, and therapeutic sensitivity and resistance.
We utilize molecular and cellular biology, immunology, sequencing, and imaging techniques in ovarian cancer cell lines, patient-derived normal and ovarian cancer organoids, and ovarian cancer mouse models.
In pursuit of this mission, the Hill lab focuses on understanding the role of the DNA damage response in ovarian carcinogenesis, tumor evolution, the anti-tumor immune response, and therapeutic sensitivity and resistance.
We utilize molecular and cellular biology, immunology, sequencing, and imaging techniques in ovarian cancer cell lines, patient-derived normal and ovarian cancer organoids, and ovarian cancer mouse models.
News and Highlights
|
We are looking for a postdoctoral fellow to join the Hill lab! If interested, please send an email to sarah_hill@dfci.harvard.edu with a cover letter, a CV, and three references who can speak to your scientific achievements. A strong work ethic and training in molecular and cellular biology are needed.
We are looking for a research assistant to join the Hill lab! If interested, please send an email to sarah_hill@dfci.harvard.edu with a cover letter, a CV, and three references who can speak to your scientific achievements. Accomplished and motivated candidates will have a B.A. in biomedical sciences and those with significant experience in molecular biology and cell biology are encouraged to apply. Follow us on Twitter @SarahJHill6 
|
-5/3/21 New Paper! Katherine Lynch in Cancers "Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M
Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1–AKT–p53 Interactions" -Dr. Hill wins the Cancer Research Early Career Award for her paper Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer -AACR recognizes Hill Lab's manuscript on novel mechanism for enhancing immune therapy efficacy in ovarian cancer -Dr. Hill featured in Tina's Wish Thank You video -Hill lab manuscript using organoid co-cultures entitled "Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high grade serous ovarian cancer" available online. -10/14/20-Dr. Hill Presents for the Society for Functional Precision Medicine 10/6/2020-Dr. Hill receives NIH Director's Early Independence Award (DP5) -10/6/20-Dr. Hill lectures in HST030 at Harvard Medical School -10/1/2020-Dr. Hill promoted to Assistant Professor of Pathology at Harvard Medical School -7/14/20-Dr. Hill presents at the Englander Institute for Precision Medicine -07/2020-Ms. Katherine Lynch joins the lab as an RA. Welcome Katherine! -03/2020-Dr. Hill receives an NIH/NCI K08 award 
|